Scotiabank Begins Coverage of Aclaris Therapeutics with Positive Outlook

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Aclaris Therapeutics (LSE:0H8T) with a Sector Outperform recommendation.

Fund Sentiment Towards Aclaris Therapeutics

A total of 135 funds and institutions currently hold positions in Aclaris Therapeutics. This figure reflects a decrease of 7 owners, or 4.93%, in the last quarter. The average portfolio weight dedicated to 0H8T among all funds is 0.24%, marking an increase of 147.60%. Additionally, the total number of shares owned by institutional investors surged by 62.42% over the past three months, reaching 89,131,000 shares.

Shareholder Activity and Changes

BML Capital Management maintains 14,250,000 shares in Aclaris, representing 13.20% ownership, with no changes reported in the last quarter.

Adage Capital Partners Gp, L.L.C. increased its holdings to 9,627,000 shares, now accounting for 8.92% ownership, up from 0 shares in its previous filing—an increase of 100.00%.

Vivo Capital also reported a significant increase, holding 8,889,000 shares for an 8.24% stake, also up from a prior report of 0 shares, indicating a 100.00% increase.

Rock Springs Capital Management reported holding 6,204,000 shares, representing a 5.75% ownership stake. This is up from their previous holding of 2,753,000 shares, reflecting a growth of 55.62%. Furthermore, the firm expanded its portfolio allocation in 0H8T by a remarkable 468.62% over the last quarter.

Ra Capital Management now holds 4,667,000 shares, which constitutes 4.32% ownership. This figure represents a substantial increase from their previous filing, where they reported owning 0 shares, also an increase of 100.00%.

Fintel is one of the most comprehensive investing research platforms, catering to individual investors, traders, financial advisors, and small hedge funds.

Our data encompasses global fundamentals, analyst reports, ownership data, fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive Stock picks leverage advanced, backtested quantitative models designed to enhance profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.